WNT11 is highly expressed in brain metastases and is associated with poor patient survival when co-expressed with ROR2. Some ROR2-positive breast cancers can be characterized by a BRCAness-like gene expression signature in a cell context-dependent manner with an enhanced susceptibility to PARP inhibition, thereby opening new possibilities for targeted treatment. This evidence concerns the gene ROR2 and breast carcinoma.